Corbus CRB-601-01 (Solid Tumors) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to find out if an experimental drug called CRB-601 (the study drug) is a safe and effective option for people who have cancers with advanced solid tumors that did not improve with standard treatment.
Advanced Solid Tumor Cancers
¿Quién puede participar en el Estudio?
Adultos de 18 a 64 años que:
- Are diagnosed with an advanced or metastatic solid tumor
- Had their disease progress after at least 1 line of previous treatment
For more information about who can join this study, please contact the Center for Cancer Immunotherapy at CCI-TrialReferrals@duke.edu.
¿Qué Implica?
If you choose to join this study, you will get an assignment to 1 of 3 different dose levels of the study drug. These dose levels might be:
- 3 milligrams for each kilogram of body weight (3 mg/kg); OR
- 10 mg/kg; OR
- 30 mg/kg
The dose level you receive will depend on when you join the study. The study team can let you know what dose level is open when you make your decision.
The study drug is given as an intravenous (IV) infusion every 2 weeks.
Detalles del Estudio
